Gain Therapeutics Management
Management criteria checks 1/4
Gain Therapeutics' CEO is Gene Mack, appointed in Apr 2024, has a tenure of less than a year. directly owns 0.054% of the company’s shares, worth $25.34K. The average tenure of the management team and the board of directors is 0.9 years and 3.9 years respectively.
Key information
Gene Mack
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.05% |
| Management average tenure | less than a year |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
May 29Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10CEO
Gene Mack
less than a year
Tenure
Mr. Gene Mack, M.B.A. is Chief Financial Officer of Gain Therapeutics, Inc. from April 8, 2024 & serves as it's Interim CEO since June 25, 2024. Mr. Mack serves as Chief Financial Officer of Imcyse SA sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.9yrs | US$99.90k | 3.51% $ 1.6m | |
| CFO & Interim CEO | less than a year | no data | 0.054% $ 25.3k | |
| Senior Vice President of Research | 2.5yrs | no data | no data | |
| Senior Vice President of Technical Operations | 3.5yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
0.9yrs
Average Tenure
Experienced Management: GANX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.9yrs | US$99.90k | 3.51% $ 1.6m | |
| Independent Director | 3.9yrs | US$86.90k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.9yrs | US$69.90k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$83.40k | 0% $ 0 | |
| Director | 4.4yrs | US$12.50k | 1.15% $ 535.8k | |
| Independent Director | 5.6yrs | US$85.40k | 0.11% $ 52.8k | |
| Independent Director | 3.9yrs | US$74.90k | 0% $ 0 |
3.9yrs
Average Tenure
68.5yo
Average Age
Experienced Board: GANX's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 07:56 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gain Therapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Keay Nakae | Chardan Capital Markets, LLC |